Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 9619205

Olanzapine.

A S Hale
View original source ↗Export metadata ↓

Abstract

Olanzapine is a newly introduced atypical neuroleptic, with a broad receptor profile similar to that of clozapine. It is as effective as haloperidol against the positive symptoms of schizophrenia, and more effective against negative symptoms, with significantly fewer extrapyramidal side-effects. Side-effects include somnolence and weight gain. It may show efficacy in treatment-resistant schizophrenia.

Explore related subjects

Antipsychotic AgentsBenzodiazepinesDosage FormsDrug ToleranceHumansOlanzapinePirenzepineSchizophreniaJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A S Hale. Olanzapine.. https://pubmed.ncbi.nlm.nih.gov/9619205/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Differential pharmacology of atypical antipsychotics: clinical implications.

PURPOSE: Pharmacology of atypical antipsychotics and the clinical implications are reviewed. SUMMARY: Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. CONCLUSION: Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders.

Antipsychotic Agents↗